Royalty Pharma Declares Fourth Quarter 2025 Dividend
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) announced a fourth-quarter 2025 dividend of $0.22 per Class A ordinary share. The board approved the dividend to shareholders of record at the close of business on November 14, 2025, with payment scheduled for December 10, 2025.
This provides a cash distribution to holders of Class A ordinary shares in Q4 2025 and sets clear record and payment dates for investors.
Positive
- $0.22 per Class A share dividend
- Payment scheduled on December 10, 2025
- Record date set at November 14, 2025
- Provides direct cash income to shareholders
Negative
- Creates a company cash outflow on December 10, 2025
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of
The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What dividend did Royalty Pharma (RPRX) declare for Q4 2025?
When will Royalty Pharma (RPRX) pay the Q4 2025 dividend?
What is the record date for Royalty Pharma's (RPRX) Q4 2025 dividend?
Who is eligible to receive Royalty Pharma's (RPRX) December 10, 2025 dividend?
How much cash will Royalty Pharma (RPRX) distribute per share for Q4 2025?
